Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Avastin: Global Drug Analysis (2016-2017) with Forecasts to 2025 - ResearchAndMarkets.com

Research and Markets
Posted on: 15 Feb 18

The "Drug analysis: Avastin" drug pipelines has been added to ResearchAndMarkets.com's offering.

Avastin (bevacizumab; Genentech/Roche/Chugai) is a humanized immunoglobulin G1 monoclonal antibody directed against vascular endothelial growth factor (VEGF).

The VEGF protein is an essential component of the angiogenesis pathway, critical for blood vessel formation, facilitating tumor growth, invasion, and metastasis. Inhibiting the VEGF protein leads to decreased blood vessel formation, thereby restricting nutrient intake and limiting tumor growth and development.

The drug was first approved for colorectal cancer in 2004, and then went on to gain approvals for lung, brain, ovarian, cervical, and renal cell cancer indications.

Key Topics Covered:

Product Profiles

  • Avastin: Colorectal cancer (CRC)
  • Avastin: Retinal disorders
  • Avastin: Ovarian cancer
  • Avastin: Glioblastoma (GBM)
  • Avastin: Renal cell cancer (RCC)
  • Avastin: Non-small cell lung cancer (NSCLC)
  • Avastin: Breast cancer: triple-negative
  • Avastin: Breast cancer: HR+/HER2-

List of Figures (25 in Total)

Figure 1: Avastin for colorectal cancer - SWOT analysis

Figure 2: Drug assessment summary of Avastin for colorectal cancer

Figure 3: Drug assessment summary of Avastin for colorectal cancer

Figure 4: Avastin sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016-25

List of Tables (27 in Total)

Table 1: Avastin drug profile

Table 2: Overview of major approvals for Avastin in colorectal cancer

Table 3: Avastin Phase III data in colorectal cancer

Table 4: Avastin sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016-25

Table 5: Patients treated with Avastin across the US, Japan, and five major EU markets, by country, 2016-25

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/wbdpgq/avastin_global?w=4

View source version on businesswire.com: http://www.businesswire.com/news/home/20180215005649/en/

Business Wire
www.businesswire.com

Last updated on: 15/02/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.